Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation comparative de la matrice dentinaire traitée dopée au silicate de calcium et de l'agrégat trioxyde minéral en tant que biomatériaux pour pulpotomie miniature dans les lésions carieuses profondes : un essai clinique parallèle, en double aveugle et randomisé. (hTDM)

8 mars 2026 mis à jour par: Ganesh Jadhav, All India Institute of Medical Sciences

Évaluation comparative de la matrice dentinaire traitée dopée au silicate de calcium et de l'agrégat trioxyde minéral comme biomatériaux de pulpotomie miniature dans les lésions carieuses profondes : un essai clinique parallèle, en double aveugle et randomisé.

OBJECTIF :

Comparer l'efficacité d'une nouvelle matrice dentinaire traitée dopée au silicate de calcium et de l'agrégat de trioxyde minéral en tant que biomatériaux pour la pulpotomie miniature.

OBJECTIFS :

Objectif principal :

Évaluer l'efficacité de la matrice dentinaire humaine traitée dopée au silicate de calcium (CaSi+hTDM) par rapport à l'agrégat de trioxyde minéral (MTA) dans le maintien de la vitalité pulpaire en utilisant un test au froid après une pulpotomie miniature (MP) dans les lésions carieuses profondes et extrêmement profondes avec pulpite réversible chez des patients âgés de 14 à 35 ans se présentant au Département de Dentisterie, AIIMS Nagpur.

Objectifs secondaires :

  1. Évaluer les résultats rapportés par les patients tels que la douleur, le gonflement, le tractus sinusal, etc. en postopératoire.
  2. Déterminer les taux de succès clinique des deux matériaux en évaluant l'indice pérapical de guérison sur une période de suivi de 6 mois.

HYPOTHÈSE NULLE :

L'hypothèse nulle (H0) est qu'il n'y a pas de différence entre le CaSi+hTDM et le MTA dans le maintien de la vitalité pulpaire lorsqu'ils sont utilisés comme biomatériau de pulpotomie miniature (MP) dans les lésions carieuses.

Aperçu de l'étude

Description détaillée

1 INTRODUCTION The loss of tooth structure significantly affects the quality of life for patients. This loss occurs due to decay and other non-carious causes. The resulting inadequate aesthetics and impaired function affects even the psychological wellbeing of the patient. Conventional root canal therapy alongside a quality coronal restoration is widely regarded as the standard treatment for this issue. Yet, traditional treatment approaches consistently present challenges such as significant periradicular dentin loss and the risk of reinfection resulting from a compromised coronal seal. Ideally reestablishment of the lost tissue to their pre-disease level should be the goal of these treatment strategies. Regeneration of the dentin-pulp complex and revitalization of the tooth as well as replacement of lost dentin by newly formed dentin should be ultimate objectives of these treatment strategies.

Caries is a biofilm mediated disease of the hard tissues of teeth that is caused by bacterial conversion of fermentable carbohydrates into acids resulting in a acidogenic and cariogenic environment which eventually breaks down the dental hard tissues to form a cavity.

Caries of the permanent teeth was reportedly the most common oral condition as per the Global Burden of Disease Study of 2017. Globally, around 2.4 billion people suffer from caries of the permanent teeth and 486 million children suffer from caries of the primary teeth. The overall prevalence for Dental caries in India is about 54.16%. However there is a remarkable variation in dental caries prevalence rates as per age, diagnostic criteria, dentition, and geographical region.

Involvement of the dentin-pulp complex in the carious process is associated with an inflammatory response. The histopathology and the pathophysiology of the diseased pulp have been extensively studied in the literature clearly illustrating that the parts of the pulpal organ under the inflamed pulpal tissue even in so called "irreversible pulpitis" remain vital or if slightly inflamed are often capable of retaining their vitality especially in the radicular portion. Therefore, there is a growing focus on conserving pulp vitality in different types of teeth with pulp involvement.

Vital pulp therapies are a collection of treatment procedures that aim to conserve the vitality of the pulpal tissue that is affected by the carious process. The procedures include removing the microbial irritation and preventing any new bacterial insult to the pulp by placement of a sealing biocompatible material to protect the pulp from external stimuli. VPT is easier and less invasive than conventional root canal treatment. However the technique is still demanding often requiring magnification and expertise.

Vital pulp therapies have become common in recent years also in part due to the development of highly biocompatible materials like MTA and various formulations of calcium silicate based materials. Calcium hydroxide based pulp therapies have nearly been replaced by MTA; MTA and calcium silicates are now recognized as the benchmark for vital pulp therapies.

A procedure termed 'miniature pulpotomy' has been proposed to improve outcomes of direct pulp capping. By removing the superficial pulp (about 1mm) under a deep carious lesion on a tooth with reversible pulpitis, infected dentin chips and inflamed pulp might be removed to give better access to highly biocompatible materials (MTA and calcium-silicate based materials) as well as provide a clean surgical wound for repair.

The ESE (European Society of Endodontology) and the AAE (American Association of Endodontists) have conflicting guidelines regarding the management of deep and extremely deep carious lesions. The ESE defines Deep caries as 'Caries reaching the inner quarter of dentine, but with a zone of hard or firm dentine between the caries and the pulp, which is radiographically detectable when located on an interproximal or occlusal surface having risk of pulp exposure during operative treatment'.

On the other hand, extremely deep caries is defined as Caries penetrating the entire thickness of the dentine, radiographically detectable when located on an interproximal or occlusal surface. Pulp exposure is unavoidable during operative treatment. The ESE position statement recommends 'Selective caries removal' whereas the AAE recommends complete caries excavation to eliminate the infection in its totality. The Indian Endodontic society (IES) considers VPT as the 'cornerstone of modern endodontics' in management of deep carious lesions and exposed pulps.

By delving into the realm of regenerative dentistry, the exploration of regenerating dental tissues through the art of tissue engineering has stood as a fervent focus of recent research. Structures resembling teeth have successfully been cultured in laboratory environments. Regeneration of dentin has been the most relevant and accessible form of tissue engineering since the dentin forming cells- the odontoblasts stay functional throughout the life of the vital tooth. Tissue engineering (TE) is a branch of regenerative medicine that combines materials science, applied cell biology, and medical engineering to replace or restore organ function. The prevailing technique in tissue engineering involves seeding cells into scaffolds. These are three-dimensional structures that serve as an extracellular matrix, creating a conducive environment for cell growth and development. Ideally, a scaffold should possess the following attributes: an appropriate surface for cell attachment, porosity and permeability to facilitate cell movement and nutrient penetration, and ultimately degrade into harmless and benign compounds. An optimal scaffold may also be shaped to direct cell adhesion, proliferation, migration, and spatial organization since scaffolds provide the blueprint for these processes.

Scaffolds, stem cells, and growth factors form the fundamental components for the regeneration of any tissue. Diverse scaffolds have been researched for dentin regeneration, encompassing synthetically-engineered polymeric and ceramic scaffolds such as synthetic polymers (PLA, PGA, PLGA) as well as naturally derived options like collagen, chitosan, cellulose, alginate, gelatin, among others.

Recently, Treated dentin matrix, an extracellular matrix-based biomaterial, has emerged as an excellent scaffold for tissue engineering because of its remarkable biological induction activity, distinct natural structure, and biocompatibility. In addition to having a high level of bioactivity, a treated dentin matrix can work as a transporter for bioactive substances and medication molecules, aiding in the processes of tissue regeneration and immunomodulation. Similar products such as demineralized bone matrices (DBMs) and other allograft bone materials have already found their place in clinical practice.

Comparative evaluation of calcium silicate-doped treated dentin matrix and mineral trioxide aggregate as miniature pulpotomy biomaterials in deep carious lesions: a parallel, double-blind, randomized clinical trial.

AIM:

To compare the efficacy of a Novel calcium silicate doped treated dentin matrix and Mineral Trioxide aggregate as biomaterials for miniature pulpotomy.

OBJECTIVES:

Primary objective:

To evaluate the efficacy of calcium silicate-doped human-treated dentin matrix (CaSi+hTDM) compared to Mineral Trioxide Aggregate (MTA) in maintaining pulp vitality using cold testing following Miniature Pulpotomy (MP) in deep and extremely deep carious lesions with reversible pulpitis in 14- to 35-year-old patients reporting to Department of Dentistry, AIIMS Nagpur.

Secondary objectives:

  1. To evaluate patient-reported outcomes such as pain, swelling, sinus tract etc. post-operatively.
  2. To determine the clinical success rates of both materials by assessing the Periapical index of healing over a 6 months follow-up period.

NULL HYPOTHESIS:

The null hypothesis (H0) is that there is no difference between CaSi+hTDM and MTA in maintaining pulp vitality when used as a Miniature Pulpotomy (MP) biomaterial in carious lesions.

Literature Review:

Vital pulp therapy is defined as a treatment aimed at conserving and sustaining compromised dental pulp tissue that has been impacted by extensive dental caries, dental trauma, and restorative interventions. or due to other iatrogenic reasons. Pulp preservation and vital pulp therapies have taken center stage in the last few years. It is important to take into consideration the entire history and genesis of pulp preservation techniques along with the newer ones that are becoming popular. Pulp preservation techniques are quite old, with reports of gold being placed directly over the injured pulp by Pfaff in the 18th century. In the early nineteenth century, the concept of pulp capping primarily revolved around the belief that pulpal healing took place solely following the etching and cauterization of the pulp. Numerous breakthroughs in the realms of medicine and technology, such as the discovery of microorganisms by Robert Hooke and Antoni van Leeuwenhoek, role of microorganisms in pathogenesis of various diseases by Pasteur and Lister, the introduction of dental radiographs in 1895 and development of anesthesia by Horace Wells and Willian Morton, has tremendously helped shape our understanding of the physiology of the pulp as well as pathology and treatment of pulpal and periapical diseases. The first clinical scientific study comparing different pulp capping materials done by Dätwyler demonstrated that zinc oxide eugenol showed the best results. After the introduction of Calcium hydroxide by Herman in 1920, numerous studies were conducted, indicating its biocompatibility when applied over vital pulp. Despite the perception in the early 1900s that an exposed pulp was deemed a 'doomed organ', it was not until research investigating pulp healing and pulpal responses to injuries and pulp capping materials were carried out, which helped in elevating our understanding of the injured pulp while also showing the unpredictability of outcomes for direct pulp capping. Success rates at that time were about 60-70% for direct pulp capping compared with 80-90% for RCT. Vital pulp treatments using calcium hydroxide had several drawbacks, such as inadequate adherence to dentin, gradual dissolution over time, and microleakage issues. However, with the introduction of Calcium silicate cements and improvement of our understanding of pulpal repair, there has been a profound change in our perspective regarding vital pulp therapies and hence this has translated to good clinical results for pulp capping and pulpotomy. Numerous great reviews have been done on the subject of Vital pulp therapies and their future directions.

Newer Definitions of VPT have been simplified to include all; 'Strategies aimed at maintaining the vitality of the pulp'. This includes one- and two-step selective caries removal techniques and indirect pulp capping to avoid pulp exposure as well as direct pulp capping and pulpotomy procedures. Recent position statements from the AAE and the ESE have provided conflicting recommendations for VPT's. The ESE position statement recommends 'selective carious-tissue removal (one-stage or two-stage stepwise technique) in teeth with reversible pulpitis, provided radiographic assessment indicates caries has progressed no deeper than the pulpal quarter with a zone of dentin separating the carious lesion from the pulp chamber'. On the contrary, the AAE recommends that 'complete caries removal is essential to eliminate infected tissues and visualize pulp tissue conditions under magnification when pulpal exposures occur. Residual caries compromises necessary observations of pulpal inflammation levels for a diagnosis of more severe pulpitis'. In instances when pulpitis was more severe, the ESE recommended that 'carious exposure with symptoms indicative of irreversible pulpitis should be treated aseptically with pulpectomy. Alternatively, full pulpotomy may be successful in cases where there is partial irreversible pulpitis in the coronal pulp; however, better long-term prospective randomized data are required'. The AAE have limited their recommendations to 'utilizing direct visualization of the pulp, it appears that even symptomatic pulps may be candidates for VPT'. Hence due to the conflicting recommendation, ways to improve the decision-making process is of paramount importance to improve the consistency and predictability of VPT. In management of deep carious lesions, carious exposures with signs and symptoms indicative of irreversible pulpitis, removal of pulp tissue either in a partial pulpotomy or full pulpotomy since the carious lesion has progressed into the pulp and there is bacterial infiltration along with concomitant pathological alterations in the pulp. Recently development of inflammatory and other biomarkers which accurately reflect the level of inflammation in the pulp offer objective means of measuring pulp inflammation. However, this requires exposure of pulp since volume retrieved from dentinal fluid in unexposed cavities is likely to be too small for analysis.

For pulp capping, calcium hydroxide was regarded for many years as the gold standard because of its potent antibacterial properties. However disadvantages included inflammation of pulpal surface and necrosis, formation of tunnel defects in newly formed dentin, high solubility in oral fluids and lack of adhesion.

MTA (Mineral Trioxide Aggregate) was first introduced in the 1990s as an experimental calcium silicate-based material. Its composition primarily comprises Portland cement, which contains tricalcium and dicalcium silicate, along with bismuth oxide serving as a radiopacifier. Commercial forms of MTA include ProRoot® MTA and tooth coloured ProRoot® MTA, (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA), and MTA Angelus® and MTA Bianco®, (Angelus, Londrina, Brazil). MTA has a variety of uses in Endodontics including being the material of choice in cases of pulp capping, pulpotomies, perforative root resorption defects, surgical root end filling, root and pulp chamber perforations and in revascularization cases MTA has demonstrated both inductive and conductive properties for promoting hard tissue formation. It also stimulates the formation of cementum-like hard tissue and contributes to bone regeneration. A randomized controlled trial, concluded that MTA exhibited greater clinical ease of use, led to reduced pulpal inflammation, and yielded more predictable outcomes for hard tissue barrier formation in comparison to calcium hydroxide for pulp capping procedures. In a meta-analysis, it was demonstrated that MTA had significantly higher success rates compared to calcium hydroxide (CH). MTA specimens exhibited lower levels of pulpal inflammation than CH specimens and showed a higher percentage of calcified dentin bridge formation as well. Despite its numerous advantages, MTA does have some drawbacks, such as challenges in handling, a prolonged setting time, higher cost, and the possibility of tooth discoloration. Biodentine (BD), developed by Septodont, France, is a calcium silicate-based Portland cement. It finds application in direct posterior restorations, addressing furcal perforations, performing retrograde filling, and for pulp capping procedures. Biodentine is regarded as a viable alternative to MTA due to its superior mechanical properties and favorable handling characteristics.

Recently, Bioceramics have been introduced like the IRoot BP Plus (Innovative Bioceramix, Vancouver, Canada) also labelled as EndoSequence Root Repair Material Putty (ERRM) (Brasseler, Savannah, GA, USA) and as TotalFill RRM Putty (FKG, La-Chaux-de-Fonds, Switzerland). The main composition of these materials being tri-calcium silicate, bi-calcium silicate and calcium phosphate. iRoot BP plus has good biocompatibility with the pulp tissue and induced formation of a reparative dentin bridge, it therefore can be used as a pulp capping material.

Various criteria are used to define the success of Vital pulp therapies in the literature. Maintenance of pulpal health both clinically and radiographically, dentin deposition over the material placed close to the pulp, absence of postoperative pain and discomfort are some of success defining criteria present in the literature.

One of the primary objectives of the vital pulp therapy is to encourage formation of a protective hard tissue barrier after an injury. The process of forming a hard tissue barrier begins with the recruitment of odontoblast-like cells from the cell-rich zone and sub-odontoblastic layer, which leads to tertiary dentin deposition under the material.

Even though currently available calcium silicate based materials support mineralization and cell growth, they are not able to provide a signal for odontogenic differentiation as well as dentin regeneration. Due to the limitations of these materials naturally derived materials have been tried. Hence, to provide a better strategy for dentin regeneration, tissue engineering concepts have been introduced for vital pulp therapies.

Scaffolds are an important part of tissue engineering. The goal of tissue engineering is to create a three-dimensional complex of biomaterials and cells that resembles biological tissue. This complex can then be utilised to replace the injured organ permanently by reconstructing its appearance, structure, and function. The triad of tissue engineering consists of a scaffold, stem cells and growth factors. Scaffolds used for dentin and pulp tissue regeneration encompass a range of materials. Natural scaffolds include collagen, glycosaminoglycan, chitosan, alginate, and agarose. Synthetic options comprise hydroxyapatite/tricalcium phosphate, polyacetic acid, polycaprolactone, and self-assembling peptide hydrogels.

Research on polysaccharide-based scaffolds like alginate scaffolds has revealed that Human Dental Pulp Cells (HDPCs) can effectively differentiate into odontoblast-like cells and stimulate calcification processes that closely mimic dentin formation. These findings support the use of alginate as a promising scaffold for dental tissue regeneration. Alginate offers several advantages, including its biocompatibility and non-immunogenic nature. However, it has disadvantages such as poor cell adhesion, low mechanical strength, and limited degradability. Chitosan is naturally found in the exoskeletons of marine crustaceans like shrimps and crabs, as well as in the cell walls of fungi. There have been conflicting findings regarding chitosan as a scaffold. While some studies have shown that a 3D chitosan scaffold supports the differentiation of Dental Pulp Stem Cells (DPSCs) due to its suitability for nerve cell attachment, other studies may have reported different outcomes or challenges with chitosan scaffolds in certain applications. But The results from Kim et al. indicated that when chitosan was compared to other natural scaffolds such as collagen and gelatin, these latter materials better supported the growth of Human Dental Pulp Cells (HDPCs). Due to its poor solubility chitosan has to be modified in order to be utilized in regenerative dentistry.

Extracellular matrix based scaffolds like hyaluronic acid is a linear polysaccharide abundant in cartilage ECM. Because of its high molecular weight, when dissolved in water, its viscoelasticity increases making it easier to be used as an injectable scaffold. Advantages include its bioactivity, biocompatibility, biodegradability and ability to act as a growth factor reservoir; disadvantages however include structural complexity, low mechanical strength and possible immunogenicity. Collagen is one of the most abundant components of extracellular matrices. Most abundant types of collagen used in tissue engineering is collagen type I and allogenic collagen such as bovine collagen which has great biocompatibility and bioactivity. Advantages of collagen include its great mechanical properties and ability of collagen to induce DPSCs into highly vascularized and organized matrix of odontoblast like cells.

Scaffolds derived from proteins include Fibrin based scaffolds like Platelet-rich fibrin (PRF) which is considered as a second generation platelet concentrate, is known to be rich in platelets, leukocytes and numerous growth factors that play an important and essential role in promoting cell proliferation and differentiation. PRF acts as a 3D mesh that can capture migrating cells and induces release of platelet derived growth factors. PRF has been tested as a pulp capping material in canines and it shows promising results for regeneration of pulp as it supplies numerous growth factors. A study compared different types of scaffolds for inducing apexogenesis in necrotic immature permanent teeth. Within the four scaffolds used, blood clot, PRF, collagen and PLGA; PRF exhibited the best results for all testing parameters. Peptides are short amino acids sequences of proteins that have biological properties. Peptides are highly customizable in regards to their biological, physical and chemical properties. Self-assembling peptides are modified peptide molecules that are self-assembled into fibrillary structures and offer advantages in regenerative endodontics like mimicking the extracellular matrix due to its nanoscale dimensions.

Growth factors(GF) are groups of proteins which bind to cell receptors and induce cellular proliferation and differentiation. It also refers to the extracellular signals that control organogenesis and morphogenesis during interactions between mesenchymal and epithelial cells. Growth factors are one of the main components of tissue engineering or any regenerative procedure. They are key factors for tissue wound healing by regulation of immune function, proliferation and differentiation of cells. Several growth factors are potential therapeutic agents for hard tissue regeneration. Some are used to increase stem cell numbers such as the platelet derived growth factors (PDGF), fibroblasts growth factors (FGF), colony stimulating factors (CSF) and epidermal growth factors (EGF). Others modulate and control humoral and cellular responses such as Interleukin-12 and Insulin-like Growth Factor 1 (IGF1) especially in activation and survival of antigen specific T cells. Dentin matrix also releases various proteins like TGF Beta-1, COL-1, DMP-1, decorin and DSP which have been found to stimulate dentinogenesis.

For pulp capping materials scaffolds can thus be mixed with growth factors and this has shown superior results enhancing reparative dentinogenesis. In a study, odontoblast-like cellular differentiation and upregulation of matrix secretion in human dentin pulp complex was shown when TGF-Beta 1 was incorporated in alginate hydrogel scaffold. When comparing the effects of MTA alone versus MTA combined with fibroblast growth factor-2 (FGF-2) in vitro on human dental pulp cell behavior, the study concluded that the MTA and FGF-2 group significantly enhanced human dental pulp cell proliferation and promoted osteogenic differentiation. Furthermore, the combination of both MTA and growth hormone (GH) was found to promote cell adhesion, growth, differentiation, and angiogenesis by activating bone morphogenetic proteins and the Mitogen-Activated Protein Kinase (MAPK) pathway.

A treated dentin matrix (TDM) is a special kind of decellularized extracellular matrix (dECM) that originates from dentin matrix (DM). A Scaffold derived from dentin is the best option we have for achieving the ideal imitation of dentin tissue. As a result, TDM has been extensively studied in recent years. TDM preserves the basic structure of natural dentinal tubules, allowing stem cells to adhere and provide the necessary space for nutrient and metabolic waste exchange. It also exposes various and abundant bio-active proteins, such as growth factors, to better induce stem cell proliferation, adhesion, and differentiation to promote dental pulp, dentin, cementum, periodontal ligament, and alveolar bone regeneration. Furthermore, TDM is able to serve as a carrier and release controller for some drug molecules and bio-active agents by taking advantage of its unique structure of exposed dentinal tubules.

In the literature several techniques have been tried for fabrication of treated dentin matrix. The essential steps in the fabrication approach for TDM are typically as follows: extraction of teeth, removal of enamel, cementum and dental pulp, sectioning into matrixes or pulverization into particles, demineralization, specific treatment (if required), sterilization, and preservation. One study detailed the different fabrication and preservation techniques. Extracted human teeth are the most common source for harvesting TDM. Studies using animal TDMs, including goats, canines, monkeys, and pigs, demonstrate that these are also feasible. It is important to remember that pig TDM and human TDM have comparable mineral phases, bioactive compounds, and odontogenic induction abilities.

In addition to this, several investigators have used special treatments on TDM and obtained various results. Studies have shown that Atelopeptidization of demineralized dentin could facilitate preserving the collagen structure and reducing the immune reaction. Another study used ethanol/DMA solution and showed that it might be capable of enhancing the mechanical properties of demineralized dentin matrix. Another study freeze dried the dentin matrix and showed that freeze-dried dentin matrix has similar mechanical and biological properties of those of dentin.

One study showed that both human dentin particulates and deproteinized bovine bone matrix supported cell proliferation in DPSCs. Another study showed a Dose-dependent promotion of cell proliferation with a higher concentration of the dentin matrix components on OD-21 cells. A treated dentin matrix paste significantly promoted cell proliferation in DPSCs in another study. However, in a different study by, treated dentin matrix extracts combined with dental pulp-cell derived small extracellular vesicles suppressed cell proliferation. Another study showed that mRNA expressions of OCN, DSPP, VEGF-1 and Nestin was upregulated by a hTDM leaching solution. Another significant study showed that TDM paste significantly enhanced the expressions of ALP, BSP and DSP in DPSCs. TDM has the capacity to cause mesenchymal stem cells to develop into osteoblasts and odontoblasts. Induced mesenchymal cells expressed more odontogenic and osteogenic-related genes and proteins.

Dental pulp stem cells (DPSCs), dental follicle cells (DFCs), cranial neural crest cells(CNCCs), umbilical cord mesenchymal stem cells(UCMSCs) and bone marrow stromal cells(BMSCs) were employed to explore the effect of a treated dentin matrix on cell differentiation by means of polymerase chain reaction, Western blot assay or immunostaining. Induction of both DFCs and DPCs by treated dentin matrix to display odontogenic differentiation potential was shown in a study.

A study has shown that new dentin was formed in a rat mandible cultured with a treated dentin matrix and DPSCs. While another showed that TDM induced DPSCs to regenerate dentin-like tissues expressing DSPP and DMP-1. Another study by the same author on DFCs showed that hTDM induced complete dentin tissue regeneration that expressed DSP and DMP-1. In a different study, the author developed a treated dentin matrix hydrogel (TDMH) for direct pulp capping, which played a role in achieving dentin regeneration while also preserving pulp vitality. CBCT showed TDMH-induced superior dentin bridge formation of higher radiodensity and thickness than Biodentine and MTA. Histological analysis showed TDMH induced thicker dentin with layers of well-arranged odontoblasts than Biodentine and MTA. In a study, it was demonstrated that Treated Dentin Matrix Paste (TDMP) stimulated the formation of a continuous reparative dentin bridge that was thicker and denser compared to calcium hydroxide. TDMP achieved both dentin regeneration and vital pulp conservation.

In conclusion, TDM is a versatile biomaterial application of which will not be restricted to the field of just dental research. Thanks to the unique porous structure and growth factors preserved within, TDM exhibits the ability to contribute to bone regeneration, soft-hard tissue interface reconstruction and immunomodulation with its own endogenous bio-active molecules and carried exogenous drugs.

Recently Calcium-silicate based materials like calcium-enriched mixture (CEM) and Biodentine have been used widely for Vital pulp therapy. CEM cement has similar physical properties to MTA and has shown PDL regeneration, cementogenesis and dentinogenesis in animal studies. It is also capable of stimulating dentinal bridge formation. Biodentine is another calcium-silicate based material that also provides complete dentinal bridge formation with absence of an inflammatory response. Calcium silicate-based materials have been demonstrated to support dental pulp stem cell proliferation and growth, while also upregulating the expression of genes such as DSPP (Dentin Sialophosphoprotein) and DMP1 (Dentin Matrix Protein 1). Hence calcium silicate is a great biocompatible material for vital pulp therapy.

The literature is scarce regarding miniature pulpotomy procedure. Only a few case reports have been published regarding this procedure, demonstrating its applicability in treating symptomatic mature molars diagnosed with irreversible pulpitis.Only a single randomized clinical trial has been done using this procedure.

MATERIALS AND METHODS:

Study Design:

This will be a prospective, block-randomized, double-blinded, and parallel-group clinical trial. The study will obtain ethical clearance from the Institutional Ethics Committee, and the protocol will be registered in the Clinical Trial Registry of India, ensuring adherence to ethical standards and transparency in research procedures. All the procedures will be followed conforming to the Helsinki Declaration of the World Medical Association. A patient information sheet and consent form will be distributed to all participants.

Study Setting:

AIIMS Nagpur is a premier medical institution in India, known for its advanced medical care, research, and education. It is located in MIHAN, Nagpur, Maharashtra. It is easily accessible via major transport links, making it convenient for participants to attend follow-up visits. The Dentistry OPD at AIIMS Nagpur serves a large number of patients daily, providing ample recruitment opportunities for study participants. It is equipped with modern dental chairs, advanced diagnostic tools (such as digital radiography), and treatment facilities. A robust electronic medical records (EMR) system ensures accurate data collection and management, facilitating longitudinal follow-up of patients. The cost of treatments available in AIIMS is affordable and minimal when compared to other hospitals and private clinics.

Clinical Setting

Treatment rooms are equipped with dental chairs and necessary

Type d'étude

Interventionnel

Inscription (Estimé)

56

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Maharashtra
      • Nagpur, Maharashtra, Inde, 441108

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte

Accepte les volontaires sains

Oui

La description

Critères d'inclusion :

  • Les participants en bonne santé (ASA 1 et 2), âgés de 14 à 35 ans, se présentant à l'AIIMS Nagpur dans un rayon de 100 km avec une exposition pulpaire carieuse dans des dents permanentes matures et présentant les caractéristiques cliniques et radiographiques suivantes seront inclus dans l'étude :

I. Caractéristiques cliniques

  1. Le diagnostic clinique de pulpite réversible caractérisé par une douleur légère (sur l'échelle d'évaluation numérique 11) qui disparaît en quelques secondes après l'arrêt du stimulus (113)
  2. Réponse positive aux tests de sensibilité pulpaire.

II. Caractéristiques radiographiques

  1. Tissus pérapicaux normaux [score de l'indice pérapical (PAI) ≤2] (114)
  2. Présence d'une lésion carieuse avec une radiotransparence pénétrant les trois quarts (carie profonde) ou toute l'épaisseur de la dentine (carie extrêmement profonde)

Critères d'exclusion :

  • Les patients présentant les caractéristiques cliniques et radiographiques suivantes seront exclus de l'étude :

I. Caractéristiques cliniques

  1. Antécédents de douleur dentaire spontanée non provoquée, douleur à la percussion, fistule, état parodontal compromis (poches parodontales > 4 mm), mobilité excessive, fêlure
  2. Hémorragie abondante sur le site d'exposition (>5 minutes)
  3. Présence d'exsudat séreux ou purulent sur le site d'exposition.
  4. Dents ayant subi une occlusion traumatique, des lésions non carieuses, des défauts de développement, etc.

II. Caractéristiques radiographiques

  1. Preuve de résorption interne ou externe, ou de calcification de la chambre pulpaire ou des canaux, ou présence d'ostéite condensante.
  2. Présence de radiotransparence dans la région de la furcation ou des régions pérapicales.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Matrice dentinaire traitée dopée au silicate de calcium pour pulpotomie miniature (CaSi+hTDM MP).

Procédure/Chirurgie : Matrice de dentine traitée dopée au silicate de calcium pour pulpotomie miniature (CaSi+hTDM MP).

Description : Matrice de dentine traitée dopée au silicate de calcium pour pulpotomie miniature (CaSi+hTDM MP).

Matrice dentinaire traitée dopée au silicate de calcium pour pulpotomie miniature (CaSi+hTDM MP).
Expérimental: Standard of Care arm : (Groupe témoin) Agrégat de trioxyde minéral (MTA) pour pulpotomie miniature
Mineral Trioxide Aggregate (MTA) pour la pulpotomie miniature (MTA MP). Le MTA sert d'intervention de référence
MTA (Agrégat Trioxyde Minéral) pour pulpotomie miniature. Le MTA sert de norme de soins.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Vitalité pulpaire
Délai: De l'inclusion jusqu'à la fin du traitement à 6 mois
Vitalité pulpaire évaluée par test au froid
De l'inclusion jusqu'à la fin du traitement à 6 mois

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

25 avril 2026

Achèvement primaire (Estimé)

1 décembre 2026

Achèvement de l'étude (Estimé)

1 avril 2027

Dates d'inscription aux études

Première soumission

11 décembre 2025

Première soumission répondant aux critères de contrôle qualité

11 décembre 2025

Première publication (Réel)

24 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 mars 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 mars 2026

Dernière vérification

1 mars 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner